MXPA02006554A - Minigenes optimizados y peptidos codificados por los mismos. - Google Patents
Minigenes optimizados y peptidos codificados por los mismos.Info
- Publication number
- MXPA02006554A MXPA02006554A MXPA02006554A MXPA02006554A MXPA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides encoded
- vaccines
- optimized
- minigenes
- optimized minigenes
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 230000005847 immunogenicity Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17339099P | 1999-12-28 | 1999-12-28 | |
| PCT/US2000/035568 WO2001047541A1 (en) | 1999-12-28 | 2000-12-28 | Optimized minigenes and peptides encoded thereby |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02006554A true MXPA02006554A (es) | 2003-09-22 |
Family
ID=22631795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02006554A MXPA02006554A (es) | 1999-12-28 | 2000-12-28 | Minigenes optimizados y peptidos codificados por los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1242108B1 (https=) |
| JP (2) | JP2004512815A (https=) |
| KR (1) | KR100838507B1 (https=) |
| CN (1) | CN1437476A (https=) |
| AT (1) | ATE366582T1 (https=) |
| AU (1) | AU780064B2 (https=) |
| BR (1) | BR0017052B1 (https=) |
| CA (1) | CA2394748A1 (https=) |
| DE (1) | DE60035523T2 (https=) |
| DK (1) | DK1242108T3 (https=) |
| ES (1) | ES2288885T3 (https=) |
| HK (1) | HK1048068B (https=) |
| MX (1) | MXPA02006554A (https=) |
| WO (1) | WO2001047541A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
| WO2004031210A2 (en) | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| CA2500715A1 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| EP1687022A4 (en) * | 2003-11-12 | 2008-02-13 | Medical Res Council | RENTA: HIV IMMUNOGEN, AND USES OF RENTA |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US9511134B2 (en) | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| EP2391635B1 (en) | 2009-01-28 | 2017-04-26 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
| GB0905519D0 (en) * | 2009-03-31 | 2009-05-13 | Biofortuna Ltd | Assay method and device |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| CA2889064A1 (en) | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| CN105254719B (zh) * | 2015-10-21 | 2018-07-13 | 黑龙江八一农垦大学 | 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗 |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| EP3744847A4 (en) * | 2018-01-22 | 2021-12-08 | Japan as Represented by The Director-General of National Institute of Infectious Diseases | SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN |
| CN112368386A (zh) * | 2018-05-23 | 2021-02-12 | 磨石肿瘤生物技术公司 | 共有抗原 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2195642A1 (en) * | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
| JP4108126B2 (ja) * | 1996-04-26 | 2008-06-25 | リュクスウニヴェルシテート テ レイデン | Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン |
| CA2250723C (en) * | 1996-05-24 | 2012-07-17 | Chiron Corporation | Multiple epitope fusion protein |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
-
2000
- 2000-12-28 MX MXPA02006554A patent/MXPA02006554A/es not_active Application Discontinuation
- 2000-12-28 AT AT00989585T patent/ATE366582T1/de active
- 2000-12-28 DK DK00989585T patent/DK1242108T3/da active
- 2000-12-28 HK HK03100192.3A patent/HK1048068B/en not_active IP Right Cessation
- 2000-12-28 DE DE60035523T patent/DE60035523T2/de not_active Expired - Lifetime
- 2000-12-28 WO PCT/US2000/035568 patent/WO2001047541A1/en not_active Ceased
- 2000-12-28 JP JP2001548133A patent/JP2004512815A/ja active Pending
- 2000-12-28 CN CN00819182A patent/CN1437476A/zh active Pending
- 2000-12-28 ES ES00989585T patent/ES2288885T3/es not_active Expired - Lifetime
- 2000-12-28 EP EP00989585A patent/EP1242108B1/en not_active Expired - Lifetime
- 2000-12-28 CA CA002394748A patent/CA2394748A1/en not_active Abandoned
- 2000-12-28 BR BRPI0017052-6B1A patent/BR0017052B1/pt not_active IP Right Cessation
- 2000-12-28 AU AU26075/01A patent/AU780064B2/en not_active Ceased
- 2000-12-28 KR KR1020027008507A patent/KR100838507B1/ko not_active Expired - Fee Related
-
2011
- 2011-03-14 JP JP2011056001A patent/JP5628716B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1048068A1 (en) | 2003-03-21 |
| JP2011168592A (ja) | 2011-09-01 |
| EP1242108A4 (en) | 2005-11-02 |
| JP5628716B2 (ja) | 2014-11-19 |
| KR20020084424A (ko) | 2002-11-07 |
| BR0017052B1 (pt) | 2013-12-24 |
| AU780064B2 (en) | 2005-02-24 |
| HK1048068B (en) | 2008-02-22 |
| ATE366582T1 (de) | 2007-08-15 |
| DE60035523T2 (de) | 2008-03-20 |
| DK1242108T3 (da) | 2007-11-12 |
| CA2394748A1 (en) | 2001-07-05 |
| JP2004512815A (ja) | 2004-04-30 |
| EP1242108A1 (en) | 2002-09-25 |
| ES2288885T3 (es) | 2008-02-01 |
| BR0017052A (pt) | 2006-03-01 |
| CN1437476A (zh) | 2003-08-20 |
| EP1242108B1 (en) | 2007-07-11 |
| DE60035523D1 (de) | 2007-08-23 |
| AU2607501A (en) | 2001-07-09 |
| WO2001047541A1 (en) | 2001-07-05 |
| KR100838507B1 (ko) | 2008-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02006554A (es) | Minigenes optimizados y peptidos codificados por los mismos. | |
| HK1049279A1 (zh) | 预防及治疗阿尔茨海默病(早老性痴呆)及淀粉样蛋白有关的病之疫苗 | |
| AU2003296330A8 (en) | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
| MY125202A (en) | Vaccine | |
| MXPA02000119A (es) | Elementos mezcladores estaticos apilados. | |
| IL210378A0 (en) | Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines | |
| AP2004003002A0 (en) | azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. | |
| WO2001051633A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| GB0123580D0 (en) | Vaccine | |
| WO2001073032A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
| WO2005039630A3 (en) | Immunogenic compositions | |
| IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| MXPA02012249A (es) | Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia. | |
| WO2001090366A3 (en) | Human polynucleotides and polypeptides encoded thereby | |
| WO2004092212A3 (en) | Tumor antigens bfa5 for prevention and/or treatment of cancer | |
| WO2004076614A3 (de) | Humane nukleinsäuresequenzen aus prostatakarzinomen | |
| GB0203420D0 (en) | Peptide | |
| AP2004003070A0 (en) | The method of treating cancer. | |
| WO2002094881A3 (en) | Monoclonal antibody neutralising cathepsin b activity and uses thereof | |
| GB0004576D0 (en) | Proteins | |
| EP1842549A3 (en) | Optimized minigenes and peptides encoded thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PHARMEXA INC. |
|
| HC | Change of company name or juridical status |
Owner name: ZILA BIOTECHNOLOGY, INC. |
|
| FA | Abandonment or withdrawal |